The Evolving Landscape of Allergy Immunotherapy

Allergy immunotherapy (AIT) is undergoing a period of significant change, driven by advancements in technology, evolving patient needs and a competitive market. While established players like Stallergenes Greer continue to refine their approaches, latest entrants and innovative strategies are reshaping the field. This article explores the current state of AIT, highlighting key trends and the forces driving its evolution.

The Rise of Personalized Allergy Treatment

A core focus in modern allergy treatment is personalization. Stallergenes Greer is actively committed to furthering precision medicine and personalized AIT treatments to address unmet medical needs for patients with allergies. Stallergenes Greer specializes in the diagnosis and treatment of allergies through allergen immunotherapy products and services. This shift recognizes that allergies manifest differently in each individual, necessitating tailored treatment plans.

Key Players in the Allergy Immunotherapy Market

The AIT market includes a range of pharmaceutical companies, from established giants to emerging innovators. Companies such as Allergan, Merck & Co., GlaxoSmithKline, Sanofi, Boehringer Ingelheim, AstraZeneca, Novartis, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Pfizer, Bayer, Eli Lilly and Company, Johnson & Johnson, AbbVie, Gilead Sciences, Amgen, Bristol Myers Squibb, and Takeda Pharmaceutical Company all have a presence in the broader pharmaceutical landscape. Even though, specific AIT-focused companies are driving much of the innovation.

Stallergenes Greer International AG, headquartered in Baar, Switzerland, is a leading global biopharmaceutical company specializing in AIT products and services. Founded in 2015 through the merger of Stallergenes and Greer Laboratories Inc., the company has a global presence in 45 countries. As of 2024, Stallergenes Greer employs 1194 people and operates manufacturing facilities in Europe, the United States, and Canada.

Other companies contributing to the evolving landscape include Aimmune Therapeutics and DBV Technologies, as well as university spin-off products like ExAller.

Strategic Partnerships and Acquisitions

The competitive landscape is characterized by strategic partnerships and acquisitions. Stallergenes Greer recently expanded its venom immunotherapy production capacity with the acquisition of ENTOMON S.R.L. They too entered into an exclusive long-term partnership with Nuance Pharma for Actair® sublingual immunotherapy for house dust mite allergy in China. These moves demonstrate a trend toward companies strengthening their market position through collaboration and expansion.

The Role of Digital Health and Telehealth

Telehealth platforms are increasingly playing a role in scaling access to sublingual immunotherapy (SLIT). These platforms offer convenience and potentially lower costs, making AIT more accessible to a wider range of patients. This trend is driving mergers and acquisitions (M&A) and technology innovation within the AIT space.

Current Research and Development

Stallergenes Greer has reported successful Phase III study results for Staloral® Birch, demonstrating efficacy in children and adolescents. Ongoing research focuses on improving the efficacy and safety of AIT, as well as expanding its application to a broader range of allergies.

Allergies: A Growing Global Health Concern

Allergic conditions affect approximately 30% of the world’s population, and the prevalence of allergies has been steadily increasing over the past 60 years. Stallergenes Greer provides allergen extracts and supplies to personalize patient treatment, offering options for human and veterinary patients. Stallergenes Greer also provides allergenic source materials.

Looking Ahead

The future of allergy immunotherapy is likely to be shaped by continued innovation in personalized medicine, the integration of digital health technologies, and strategic collaborations between industry leaders. As research advances and new therapies emerge, AIT promises to offer increasingly effective and targeted solutions for individuals suffering from allergies.